StockData
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc (BMRN) stock

BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30101% above fair value
$60.41−1.01 (-1.64%)

Close on Nov 20, 2026Market cap $11.69BP/E 159.0Yield –

BioMarin Pharmaceutical free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

BioMarin Pharmaceutical's free cash flow for the twelve months ending Jun 30, 2026 was $738.18M, up 6.2% year over year. For fiscal 2025 it was $724.96M, up 48.7% from the year before. The highest annual figure on record is $724.96M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$724.96M+48.7%
FY2024Dec 31, 2024$487.42M+679.0%
FY2023Dec 31, 2023$62.57M+13.9%
FY2022Dec 31, 2022$54.94M-73.7%
FY2021Dec 31, 2021$208.96M–
FY2020Dec 31, 2020-$28.95M–
FY2019Dec 31, 2019-$96.76M–
FY2018Dec 31, 2018-$124.41M–
FY2017Dec 31, 2017-$207.98M–
FY2016Dec 31, 2016-$376.22M–
FY2015Dec 31, 2015-$447.15M–
FY2014Dec 31, 2014-$187.48M–
FY2013Dec 31, 2013-$122.53M–
FY2012Dec 31, 2012-$26.96M–
FY2011Dec 31, 2011-$54.80M–
FY2010Dec 31, 2010-$30.72M–
FY2009Dec 31, 2009-$2.07M–
FY2008Dec 31, 2008-$65.54M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$139.29M-17.2%
Q1 FY2026Mar 31, 2026$199.73M+26.7%
Q4 FY2025Dec 31, 2025$58.92M-64.5%
Q3 FY2025Sep 30, 2025$340.24M+67.6%
Q2 FY2025Jun 30, 2025$168.17M+72.6%
Q1 FY2025Mar 31, 2025$157.63M+655.4%
Q4 FY2024Dec 31, 2024$166.10M–
Q3 FY2024Sep 30, 2024$203.02M+78.2%
Q2 FY2024Jun 30, 2024$97.44M+101.0%
Q1 FY2024Mar 31, 2024$20.87M–
Q4 FY2023Dec 31, 2023-$1.43M–
Q3 FY2023Sep 30, 2023$113.91M-11.7%
Q2 FY2023Jun 30, 2023$48.48M+66.8%
Q1 FY2023Mar 31, 2023-$98.39M–
Q4 FY2022Dec 31, 2022-$28.90M–
Q3 FY2022Sep 30, 2022$129.02M+64.7%
Q2 FY2022Jun 30, 2022$29.07M-51.7%
Q1 FY2022Mar 31, 2022-$74.25M-184.4%
Q4 FY2021Dec 31, 2021-$17.56M–
Q3 FY2021Sep 30, 2021$78.33M+12.5%
Q2 FY2021Jun 30, 2021$60.19M+3721.3%
Q1 FY2021Mar 31, 2021$88.01M–
Q4 FY2020Dec 31, 2020-$44.41M-777.2%
Q3 FY2020Sep 30, 2020$69.64M+86.8%
Q2 FY2020Jun 30, 2020$1.58M–
Q1 FY2020Mar 31, 2020-$55.75M–
Q4 FY2019Dec 31, 2019$6.56M-10.1%
Q3 FY2019Sep 30, 2019$37.27M–
Q2 FY2019Jun 30, 2019-$56.97M–
Q1 FY2019Mar 31, 2019-$83.62M–
Q4 FY2018Dec 31, 2018$7.30M–
Q3 FY2018Sep 30, 2018-$2.66M–
Q2 FY2018Jun 30, 2018-$56.38M–
Q1 FY2018Mar 31, 2018-$72.67M–
Q4 FY2017Dec 31, 2017-$25.28M–
Q3 FY2017Sep 30, 2017-$4.19M–
Q2 FY2017Jun 30, 2017-$28.98M–
Q1 FY2017Mar 31, 2017-$149.53M–
Q4 FY2016Dec 31, 2016-$51.78M–
Q3 FY2016Sep 30, 2016-$36.46M–

More BioMarin Pharmaceutical figures

See a number that looks wrong?